MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Cytek Biosciences Inc

Geschlossen

BrancheGesundheitswesen

5.39 -3.92

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

5.38

Max

5.48

Schlüsselkennzahlen

By Trading Economics

Einkommen

105K

-5.5M

Verkäufe

6.7M

52M

EPS

-0

Gewinnspanne

-10.476

Angestellte

692

EBITDA

6.4M

-4.2M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+10.97% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

26. Feb. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

240M

742M

Vorheriger Eröffnungskurs

9.31

Vorheriger Schlusskurs

5.39

Nachrichtenstimmung

By Acuity

17%

83%

18 / 361 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Cytek Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

16. Jan. 2026, 23:29 UTC

Heiße Aktien

Stocks to Watch: Atossa Therapeutics, Union Pacific

16. Jan. 2026, 22:48 UTC

Akquisitionen, Fusionen, Übernahmen

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16. Jan. 2026, 22:43 UTC

Akquisitionen, Fusionen, Übernahmen

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16. Jan. 2026, 22:22 UTC

Akquisitionen, Fusionen, Übernahmen

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16. Jan. 2026, 21:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

16. Jan. 2026, 21:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Auto & Transport Roundup: Market Talk

16. Jan. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16. Jan. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

16. Jan. 2026, 21:48 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16. Jan. 2026, 21:41 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16. Jan. 2026, 21:38 UTC

Akquisitionen, Fusionen, Übernahmen

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16. Jan. 2026, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16. Jan. 2026, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16. Jan. 2026, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16. Jan. 2026, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16. Jan. 2026, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16. Jan. 2026, 20:44 UTC

Ergebnisse

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16. Jan. 2026, 20:42 UTC

Market Talk

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16. Jan. 2026, 20:28 UTC

Market Talk

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16. Jan. 2026, 19:12 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16. Jan. 2026, 18:53 UTC

Market Talk

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16. Jan. 2026, 18:41 UTC

Market Talk

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16. Jan. 2026, 18:31 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16. Jan. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

16. Jan. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

16. Jan. 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

16. Jan. 2026, 17:03 UTC

Market Talk

Global Equities Roundup: Market Talk

16. Jan. 2026, 17:03 UTC

Market Talk

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16. Jan. 2026, 16:32 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16. Jan. 2026, 16:20 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Cytek Biosciences Inc Prognose

Kursziel

By TipRanks

10.97% Vorteil

12-Monats-Prognose

Durchschnitt 6.17 USD  10.97%

Hoch 7.5 USD

Tief 5 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cytek Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

3 ratings

2

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

3.7 / 3.8Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

18 / 361 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat